Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis
Toxicological Sciences · 26.06.2024 · 200 (1) · 11-30
DOI: 10.1093/toxsci/kfae046 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Toxicological Sciences, online erschienen am 08.04.2024. Verfasst von Marc Pallardy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, INSERM, Inflammation Microbiome Immunosurveillance, Orsay, 91400, France. Hauptthemen laut MEDLINE: Drug Hypersensitivity. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Drug hypersensitivity reactions (DHRs) are a type of adverse drug reaction that can occur with different classes of drugs and affect multiple organ systems and patient populations. DHRs can be classified as allergic or non-allergic based on the cellular mechanisms involved. Whereas nonallergic reactions rely mainly on the innate immune system, allergic reactions involve the generation of an adaptive immune response. Consequently, drug allergies are DHRs for which an immunological mechanism, with antibody and/or T cell, is demonstrated. Despite decades of research, methods to predict the potential for a new chemical entity to cause DHRs or to correctly attribute DHRs to a specific mechanism and a specific molecule are not well-established. This review will focus on allergic reactions induced by systemically administered low-molecular weight drugs with an emphasis on drug- and patient-specific factors that could influence the development of DHRs. Strategies for predicting and diagnosing DHRs, including potential tools based on the current state of the science, will also be discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Université Paris-Saclay, INSERM, Inflammation Microbiome Immunosurveillance, Orsay, 91400, France.
- Université Paris-Saclay, INSERM, CEA, Center for Research in Immunology of Viral, Autoimmune, Hematological and Bacterial Diseases (IMVA-HB), Le Kremlin Bicêtre, 94270, France.
- Pfizer Worldwide Research, Development and Medical, Groton, Connecticut 06340, USA.
- The Health and Environmental Science Institute, Immunosafety Technical Committee, Washington, District of Columbia 20005, USA.
- Merck & Co., Inc, West Point, Pennsylvania 19486, USA.
- Amgen Inc., Translational Safety and Bioanalytical Sciences, South San Francisco, California 94080, USA.
Zitieren
APA
Pallardy, M., Bechara, R., Whritenour, J., Mitchell-Ryan, S., Herzyk, D., Lebrec, H., Merk, H., Gourley, I., Komocsar, W. J., Piccotti, J. R., Balazs, M., Sharma, A., Walker, D. B., & Weinstock, D. (2024). Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis. Toxicological Sciences, 200(1), 11-30. https://doi.org/10.1093/toxsci/kfae046
Vancouver
Pallardy M, Bechara R, Whritenour J, Mitchell-Ryan S, Herzyk D, Lebrec H, et al. Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis. Toxicological Sciences. 2024;200(1):11-30. doi:10.1093/toxsci/kfae046
BibTeX
@article{Pallardy2024,
author = {Pallardy, Marc and Bechara, Rami and Whritenour, Jessica and Mitchell-Ryan, Shermaine and Herzyk, Danuta and Lebrec, Herve and Merk, Hans and Gourley, Ian and Komocsar, Wendy J and Piccotti, Joseph R and Balazs, Mercedesz and Sharma, Amy and Walker, Dana B and Weinstock, Daniel},
title = {Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis},
journal = {Toxicological Sciences},
year = {2024},
volume = {200},
number = {1},
pages = {11--30},
doi = {10.1093/toxsci/kfae046}
}
EUVIMED